Medical devices, healthcare technology and the business of care
510(k) clearance · K261398

Dexter L6 System

Distalmotion SA · Decision date Aug 11, 2026

FDA DECISIONK261398

What did the FDA decide?

FDA records K261398 as a 510(k) premarket notification, with a decision dated Aug 11, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
General, Plastic Surgery
Decision date
Aug 11, 2026

FDA source record

Regulatory record facts

Identifier
K261398
Regulatory pathway
510(k) premarket notification
Product code
SDD
Decision code
SESE
Decision date
Aug 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Electromechanical Surgical System Wherein The Surgeon Annd The User Interface Can Be In The Sterile Field.

Product code
SDD
FDA device class
2

FDA decision timeline

  1. K261398 received

    Application receipt date recorded by FDA.

  2. K261398 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code SDD

Product / regulatory recordCompanyPathwayDecision dateSource
Distalmotion SA510(k) clearanceJun 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Distalmotion SA

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Epalinges

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records